Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
AssigneeDeciphera Pharmaceuticals, LLC
InventorsMichael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Life of this patent
Estimating the term…
Abstract
Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Claims5
A pharmaceutical solid dispersion composition comprising:
- a) a solid dispersion comprising:
- a pharmaceutically acceptable polymer;
- and
- an amorphous form of a compound represented by Formula (I)
- and
- b) one or more pharmaceutically acceptable carriers;
- wherein:
- a compound represented by Formula (II):
- is present in the solid dispersion composition in amount of about 0.1% (w/w) to about 0.5% (w/w) by weight based on the total weight of the solid dispersion composition;
- and
- aniline and diphenyl urea are each present in amount equal to or less than about 0.5% by weight based on the total weight of solid dispersion composition.
A pharmaceutically acceptable composition for orally delivering to a patient 50 mg of a compound represented by Formula (I):
- comprising:
- a solid dispersion comprising:
- 50 mg of the compound wherein the compound is present in amorphous form;
- hydroxypropyl methyl cellulose acetate succinate;
- a bulking agent, a filler, and a lubricant;
- wherein diphenyl urea is present in amount equal to or less than about 0.5% by weight based on the total weight of the composition.
A pharmaceutically acceptable composition for orally delivering to a patient 50 mg of a compound represented by Formula (I):
- comprising:
- a) a solid dispersion having:
- 50 mg of the compound wherein the compound is present in amorphous form;
- hydroxypropyl methyl cellulose acetate succinate;
- and
- b) a pharmaceutically acceptable carrier;
- wherein a compound represented by Formula (II):
- is present in composition in amount equal to or less than about 0.5% by weight based on the total weight of the composition.
A pharmaceutically acceptable composition for orally delivering 50 mg of a compound represented by Formula (I):
- comprising:
- a solid dispersion having 50 mg of the compound wherein the compound is present in amorphous form, and a polymer;
- about 25-45% by weight of a bulking agent based on the total amount of the pharmaceutical composition;
- about 25-45% by weight of a filler based on the total amount of the pharmaceutical composition;
- and
- a glidant and/or a lubricant;
- wherein when exposed to 60% relative humidity at 25° C. for 1 month, the composition has not more than about 0.5% (w/w) of a compound represented by Formula (II):
Dependencies are inferred from the claim text.